Intestinal growth factors: Potential use in the treatment of inflammatory bowel disease and their role in mucosal healing

Inflammatory Bowel Diseases

Volumn 17, Issue 1, 2011, Pages 410-422

  Krishnan, Kumar ^a   Arnone, Baron ^a   Buchman, Alan ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Crohn's disease; epidermal growth factor (EGF); GCSF; glucagon like peptide 2 (GLP 2); GMCSF; growth factors; human growth hormone (HGH); IBD; keratinocyte growth factor (KGF); transforming growth factor (TGF); trefoil factor; ulcerative colitis; vascular endothelial growth factor (VEGF)

Indexed keywords

AZATHIOPRINE; BONE MORPHOGENETIC PROTEIN; CORTICOSTEROID; DEXTRAN SULFATE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GLUCAGON LIKE PEPTIDE 2; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; INTESTINAL TREFOIL FACTOR; KERATINOCYTE GROWTH FACTOR; MERCAPTOPURINE; MESALAZINE; PLACEBO; PREDNISONE; RECOMBINANT EPIDERMAL GROWTH FACTOR; RECOMBINANT GROWTH FACTOR; RECOMBINANT GROWTH HORMONE; RECOMBINANT OSTEOGENIC PROTEIN 1; REPIFERMIN; STEROID; TEDUGLUTIDE; TRANSFORMING GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; TRINITROBENZENESULFONIC ACID; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ADENOMA; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CELL PROLIFERATION; CHRONIC NEPHRITIS; CLINICAL EVALUATION; CLINICAL TRIAL; COHORT ANALYSIS; COLITIS; COLON; CRHONIC NEPHRITIS; CROHN DISEASE; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ENTERITIS; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE; INTESTINE CELL; INTESTINE MUCOSA; KIDNEY FIBROSIS; NEOPLASM; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; REMISSION; REVIEW; SHORT BOWEL SYNDROME; TREATMENT OUTCOME; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; WOUND HEALING;

HUMANS; INFLAMMATORY BOWEL DISEASES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTESTINAL MUCOSA; INTESTINES; WOUND HEALING;

EID: 78650150602     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21316     Document Type: Review

References (96)

1. Wu MY, Hill CS,. Tgf-beta superfamily signaling in embryonic development and homeostasis. Dev Cell. 2009; 16: 329-343.
2. Feng XH, Derynck R,. Specificity and versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev Biol. 2005; 21: 659-693.
3. Khalil N,. TGF-beta: from latent to active. Microbes Infect. 1999; 1: 1255-1263.
4. Yeo C, Whitman M,. Nodal signals to Smads through Cripto-dependent and Cripto-independent mechanisms. Mol Cell. 2001; 7: 949-957.
5. Goumans MJ, Valdimarsdottir G, Itoh S, et al. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J. 2002; 21: 1743-1753.
6. Ross S, Hill CS,. How the Smads regulate transcription. Int J Biochem Cell Biol. 2008; 40: 383-408.
7. Seoane J, Le HV, Shen L, et al. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell. 2004; 117: 211-223.
8. Gomis RR, Alarcõn C, Nadal C, et al. C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell. 2006; 10: 203-214.
9. Kang Y, Chen CR, Massague J,. A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol Cell. 2003; 11: 915-926.
10. Babyatsky MW, Rossiter G, Podolsky K,. Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology. 1996; 110: 975-984.
11. Maric I, Poljak L, Zoricic S,. Bone morphogenetic protein-7 reduces the severity of colon tiwsue damage and accelerates the healing of inflammatory bowel disease in rats. J Cell Physiol. 2003; 196: 258-264.
12. Zeisberg M, Hanai J, Sugimoto H, et al. BMP-7 counteracts TGF-B1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med. 2003; 9: 964-968.
13. Herrington J, Carter-Su C,. Signaling pathways activated by the growth hormone receptor. Trends Endocrinol Metab. 2001; 12: 252-257.
14. Rosenfeld RG, Kofoed E, Buckway C, et al. Identification of the first patient with a confirmed mutation of the JAK-STAT system. Pediatr Nephrol. 2005; 20: 303-305.
15. Costoya JA, Finidori J, Moutoussamy S, et al. Activation of growth hormone receptor delivers an antiapoptotic signal: evidence for a role of Akt in this pathway. Endocrinology. 1999; 140: 5937-5943.
16. Woelfle J, Chia DJ, Rotwein P,. Mechanisms of growth hormone (GH) action. Identification of conserved Stat5 binding sites that mediate GH-induced insulin-like growth factor-I gene activation. J Biol Chem. 2003; 278: 51261-51266.
17. Zhu T, Ling L, Lobie PE,. Identification of a JAK2-independent pathway regulating growth hormone (GH)-stimulated p44/42 mitogen-activated protein kinase activity. GH activation of Ral and phospholipase D is Src-dependent. J Biol Chem. 2002; 277: 45592-45603.
18. Delehaye-Zervas MC, Mertani H, Martini JF, et al. Expression of the growth hormone receptor gene in human digestive tissue. J Clin Endocrinol Metab. 1994; 78: 1473-1480.
19. Theiss AL, Fruchtman S, Lund PK,. Growth factors in inflammatory bowel disease. The actions and interactions of growth hormone and insulin-like growth factor-I. Inflamm Bowel Dis. 2006; 10: 871-880.
20. Han X, Sosnowska D, Bonowski EL, Denson LA,. Growth hormone inhibits signal transducer and activator of transcription 3 activation and reduces disease activity in murine colitis. Gastroenterology. 2005; 129: 185-203.
21. Williams KL, Fuller CR, Dieleman LA, et al. Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that overexpress growth hormone. Gastroenterology. 2001; 120: 925-937.
22. Kara E, Sungurtekin H, Sungurtekin U, et al. The effect of recombinant human growth hormone (rhGH) on trinitrobenzene sulfonic acid-induced colitis in rats: an experiment study. Inflamm Bowel Dis. 2004; 10: 112-115.
23. Theiss AL, Fuller CR, Simmons JG, et al. Growth hormone reduces the severity of fibrosis associated with chronic intestinal inflammation. Gastroenterology. 2005; 129: 204-219.
24. Heyman MB, Garnett EA, Wojcicki J, et al. Growth hormone treatment for growth failure in pediatric patients with Crohn's disease. J Pediatr. 2008: 651-658.
25. Calenda KA, Schornagel IL, Sadeghi-Nejad A, Grand RJ,. Effect of recombinant growth hormone treatment on children with Crohn's disease and short stature: a pilot study. Inflamm Bowel Dis. 2005; 11: 435-441.
26. Ellegard L, Bosaeus I, Nordgren S, Bengtsson BA,. Low-dose recombinant human growth hormone increases body weight and lean body mass in patients with short bowel syndrome. Ann Surg. 1997; 225: 88-96.
27. Mauras N, George D, Evans J, et al. Growth hormone has anabolic effects in glucocorticosteroid-dependent children with inflammatory bowel disease: a pilot study. Metab Clin Exp. 2002; 51: 127-135.
28. McCafferty TD, Nasr K, Lawrence AM, Kirsner JB,. Effect of administered human growth hormone on growth retardation in inflammatory bowel disease. Am J Dig Dis. 1974; 19: 411-416.
29. Slonim AE, Bulone L, Damore MB, et al. A preliminary study of growth hormone therapy for Crohn's disease. N Engl J Med. 2000; 342: 1633-1637.
30. Gregory H,. Isolation and structure of urogastrone and its relationship to epidermal growth factor. Nat Med. 1975; 257: 325-327.
31. Paul L, Beck DP,. Growth factors in inflammatory bowel disease. Inflamm Bowel Dis. 1999; 5: 44-60.
32. Citri A, Yarden Y,. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006; 7: 505-516.
33. Gadella TW Jr, Jovin TM,. Oligomerization of epidermal growth factor receptors on A431 cells studied by time-resolved fluorescence imaging microscopy. A stereochemical model for tyrosine kinase receptor activation. J Cell Biol. 1995; 129: 1543-1558.
34. Schulze WX, Deng L, Mann M,. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol. 2005; 1: 2005 0008.
35. Jones RB, Gordus A, Krall JA, MacBeath G,. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature. 2006; 439: 168-174. (Pubitemid 43083134)
36. Burgess AW, Cho HS, Eigenbrot C, et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell. 2003; 12: 541-552.
37. Procaccino F, Reinshagen M, Hoffman P, et al. Protective effect of epidermal growth factor in an experimental model of colitis in rats. Gastroenterology. 1994; 107: 12-17.
38. Sinha A, Nightingale J, West KP, et al. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med. 2003; 349: 350-357.
39. Kim TY, Han DS, Eun CS, Chung YW,. Recombinant human epidermal growth factor enhances wound healing of pyoderma gangrenosum in a patient with ulcerative colitis. Inflamm Bowel Dis. 2008; 14: 725-727.
40. Eswarakumar VP, Lax I, Schlessinger J,. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005; 16: 139-149.
41. Hadari YR, Gotoh N, Kouhara H, et al. Critical role for the docking-protein FRS2 alpha in FGF receptor-mediated signal transduction pathways. Proc Natl Acad Sci U S A. 2001; 98: 8578-8583.
42. Kouhara H, Hadari YR, Spivak-Kroizman T, et al. A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell. 1997; 89: 693-702.
43. Orr-Urtreger A, Bedford MT, Burakova T, et al. Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2). Dev Biol. 1993. 158: 475- 486.
44. Zhang X, Ibrahim OA, Olsen SK, et al. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem. 2006; 281: 15694-15700.
45. Bajaj-Elliott M, Breese E, Poulsom R, et al. Keratinocyte growth factor in inflammatory bowel disease. Am J Pathol. 1997; 151.
46. Miceli R, Hubert M, Santiago G, et al. Efficacy of keratinocyte growth factor-2 in dextran sulfate sodium-induced murine colitis. J Pharmacol Exp Ther. 1999; 290: 464-471.
47. Egger B, Procaccino F, Sarosi I, et al. Keratinocyte growth factor ameliorates dextran sodium sulfate colitis in mice. Dig Dis Sci. 1999; 44: 836-844.
48. Greenwood-Van Meerveld VK, Connolly K,. Efficacy of repifermin (keratinocyte growth factor-2) against abnormalities in gastrointestinal mucosal transport in a murine model of colitis. J Pharm Pharmacol, 2003; 55.
49. Sandborn WJ, Sands BE, Wolf DC, et al. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther. 2003; 17: 1355-1364.
50. Dhanvantari S, Seidah NG, Brubaker PL,. Role of prohormone convertases in the tissue-specific processing of proglucagon. Mol Endocrinol. 1996; 10: 342-355.
51. Hartmann B, Harr MB, Jeppesen PB, et al. In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab. 2000; 85: 2884-2888.
52. Drucker DJ, Shi Q, Crivici A, et al. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol. 1997; 15: 673-677.
53. Munroe DG, Guptka AK, Kooshesh F, et al. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci U S A. 1999; 96: 1569-1573.
54. Bjerknes M, Cheng H,. Modulation of specific intestinal epithelial progenitors by enteric neurons. Proc Natl Acad Sci U S A. 2001; 98: 12497-12502.
55. Koehler JA, Yusta B, Drucker DJ,. The HeLa cell glucagon-like peptide-2 receptor is coupled to regulation of apoptosis and ERK1/2 activation through divergent signaling pathways. Mol Endocrinol. 2005; 19: 459-473.
56. Walsh NA, Yusta B, DaCambra MP, et al. Glucagon-like peptide-2 receptor activation in the rat intestinal mucosa. Endocrinology. 2003; 144: 4385-4392.
57. Yusta B, Estall J, Drucker DJ,. Glucagon-like peptide-2 receptor activation engages bad and glycogen synthase kinase-3 in a protein kinase A-dependent manner and prevents apoptosis following inhibition of phosphatidylinositol 3-kinase. J Biol Chem. 2002; 277: 24896-24906.
58. Yusta B, Huang L, Munroe D, et al. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology. 2000; 119: 744-755.
59. Brubaker PL, Izzo M, Hill M, Drucker DJ,. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol. 1997; 272: E1050-E1058.
60. Cheeseman CI,. Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo. Am J Physiol. 1997; 273: R1965-R1971.
61. Drucker DJ, Erlich P, Asa SL, Brubaker PL,. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A. 1996; 93: 7911-716.
62. Garrison AP, Dekaney CM, von Allmen DC, et al. Early but not late administration of glucagon-like peptide-2 following ileo-cecal resection augments putative intestinal stem cell expansion. Am J Physiol Gastrointest Liver Physiol. 2009; 296: G643-G650.
63. Jeppesen PB, Hartmann B, Thulesen J, et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology. 2001; 120: 806-815.
64. Jeppesen PB, Sanguinetti EL, Buchman A, et al. Teduglutide (ALX-0600), a dipeptidyl peptidase-IV resistant glucagon-like peptide-2 analogue, improves intestinal function in short bowel syndrome patients. Gut. 2005; 54: 1224-1231.
65. Buchman AL, et al. Effect of teduglutide on patients with moderate-severe Crohn's disease after 8 weeks of therapy: a prospective, double-blind, placebo-controlled trial. Gastroenterology. 2006; 131: 949-950.
66. Geijsen N, Koenderman L, Coffer PJ,. Specificity in cytokine signal transduction: lessons learned from the IL-3/IL-5/GM-CSF receptor family. Cytokine Growth Factor Rev. 2001; 12: 19-25.
67. Ebner K, Bandion A, Binder BR, et al. GMCSF activates NF-kappaB via direct interaction of the GMCSF receptor with IkappaB kinase beta. Blood. 2003; 102: 192-199.
68. Dijkers PF, van Dijk TB, de Groot RP, et al. Regulation and function of protein kinase B and MAP kinase activation by the IL-5/GM-CSF/IL-3 receptor. Oncogene. 1999; 18: 3334-3342.
69. Fukuzawa H, Sawada M, Kayahara T, et al. Identification of GM-CSF in Paneth cells using single-cell RT-PCR. Biochem Biophys Res Commun. 2003; 312: 897-902.
70. Ramsay RG, Micallef SJ, Williams B, et al. Colony-stimulating factor-1 promotes clonogenic growth of normal murine colonic crypt epithelial cells in vitro. J Interferon Cytokine Res. 2004; 24: 416-427.
71. Liu F, Wu HY, Wesselschmidt R, et al. Impaired production and increased apoptosis of neutrophils in granulocyte colony-stimulating factor receptor-deficient mice. Immunity. 1996; 5: 491-501.
72. Egi H, Hayamizu K, Yoshimitsu M, et al. Regulation of T helper type-1 immunity in hapten-induced colitis by host pretreatment with granulocyte colony-stimulating factor. Cytokine. 2003; 23: 23-30.
73. Kudo T, Matsumoto T, Nakamichi I, et al. Recombinant human granulocyte colony-stimulating factor reduces colonic epithelial cell apoptosis and ameliorates murine dextran sulfate sodium-induced colitis. Scand J Gastroenterol. 2008; 43: 689-697.
74. Sainathan SK, Hanna EM, Gong Q, et al. Granulocyte macrophage colony-stimulating factor ameliorates DSS-induced experimental colitis. Inflamm Bowel Dis. 2008; 14: 88-99.
75. Bernasconi E, Favre L, Maillard MH, et al. Granulocyte-macrophage colony-stimulating factor elicits bone marrow-derive cells that promote efficient colonic mucosal healing. Inflamm Bowel Dis. 2010; 16: 428-441.
76. Dieckgraefe BK, Korzenik JR,. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet. 2002; 360: 1478-80.
77. Korzenik JR, Diekegraef BK, Valentine JF, et al. Sargramostim for active Crohn's disease. N Engl J Med. 2005; 352: 2193-2201.
78. Valentine JF, Fedorak RN, Feagan B, et al. Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study. Gut. 2009; 58: 1354-62.
79. Dejaco C, Lichtenberger C, Miehsler W, et al. An open-label pilot study of granuloscyte colony-stimulating factor for the treatment of severe endoscopic postoperative recurrence in Crohn's disease. Digestion. 2003; 68: 63-70.
80. Korzenik JR, Dieckgraefe BK,. An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease. Aliment Pharmacol Therap. 2005; 21.
81. Matsumoto T, Mugishima H,. Signal transduction via vascular endothelial growth factor (VEGF) receptors and their roles in atherogenesis. J Atheroscler Thromb. 2006; 13: 130-135.
82. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996; 380: 435-439.
83. Scaldaferri F, Vetrano S, Sans M, et al. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology. 2009; 136: 585-595.
84. Tolstanova G, Khomenko T, Deng X, et al. Neutralizing anti-vascular endothelial growth factor (VEGF) antibody reduces severity of experimental ulcerative colitis in rats: direct evidence for the pathogenic role of VEGF. J Pharmacol Exp Ther. 2009; 328: 749-757.
85. Scaldaferri F, Vetrano S, Sans M, et al. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease. Gastroenterology. 2009; 136: 585-595.
86. Wong WM, Poulsom R, Wright NA,. Trefoil peptides. Gut. 1999; 44: 890-895.
87. Tanaka S, Podolsky DK, Engel E, et al. Human spasmolytic polypeptide decreases proton permeation through gastric mucus in vivo and in vitro. Am J Physiol. 1997; 272: G1473-G1480.
88. Kindon H, Pothoulakis C, Thim L, et al. Trefoil peptide protection of intestinal epithelial barrier function: cooperative interaction with mucin glycoprotein. Gastroenterology. 1995; 109: 516-523.
89. Playford RJ, Marchbank T, Chinery R, et al. Human spasmolytic polypeptide is a cytoprotective agent that stimulates cell migration. Gastroenterology. 1995; 108: 108-116.
90. Dubeykovskaya Z, Dubeykovskiy A, Solal-Cohen J, Wang TC,. Secreted trefoil factor 2 activates the CXCR4 receptor in epithelial and lymphocytic cancer cell lines. J Biol Chem. 2009; 284: 3650-3662.
91. Playford RJ, Marchbank T, Goodland RA, et al. Transgenic mice that overexpress the human trefoil peptide pS2 have an increased resistance to intestinal damage. Proc Natl Acad Sci U S A. 1996; 93: 2137-2142.
92. Mashimo H, Wu DC, Podolsky DK, Fishman MC,. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science. 1996; 274: 262-266.
93. Tran CP, Cook GA, Yeomans ND, et al. Trefoil peptide TFF2 (spasmolytic polypeptide) potently accelerates healing and reduces inflammation in a rat model of colitis. Gut. 1999; 44: 636-642.
94. Poulsen SS, Kissow H, Hare K, et al. Luminal and parenteral TFF2 and TFF3 dimer and monomer in two models of experimental colitis in the rat. Regul Pept. 2004; 126: 163-171.
95. Mahmood A, Melley L, Fitzgerald AJ, et al. Trial of trefoil factor 3 enemas, in combination with oral 5-aminosalicylic acid, for the treatment of mild-to-moderate left-sided ulcerative colitis. Aliment Pharmacol Therapeut. 2005; 21: 1357-1364.
96. Vandenbroucke K, Hans W, Van Huysse J, et al. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology. 2004; 127: 502-513.